Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode,Drs Elizabeth Bukusi, Peter Godfrey-Faussett, and Nina Russell discuss promising advances in the field of HIV vaccine research and how we can prepare for optimal rollout of an eventual HIV vaccine. Presenters:Elizabeth Anne Bukusi, MBChB, M.Med (ObGyn), MPH, PhD , PGD (Research Ethics), MBE (Research Ethics), CIPSenior Principal Clinical Research ScientistCenter for Microbiology ResearchKEMRIResearch ProfessorDepartments of Global Health and Obstetrics and GynecologyUniversity of Washington,Nairobi, KenyaSeattle, WashingtonPeter Godfrey-Faussett, MBBS, FRCP(UK)Science AdvisorUnited Nations Joint Programme on HIV (UNAIDS)Professor of Infectious Diseases and International HealthLondon School of Hygiene and Tropical MedicineLondon, United KingdomNina Russell, MDDirector for TB and HIV PreventionBill & Melinda Gates FoundationSeattle, WashingtonLink to full series: https://bit.ly/2UgrQ12Link to the HIV unmuted series from IAS: https://hivunmuted.iasociety.org/Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related